Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN211745 in wet AMD
NCT00395057Phase 2Terminated
- Sponsor
- Allergan
- Start
- Jan 2007
- Primary completion
- Oct 2008
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
Phase 2, randomised trial of Sirna-027 in exudative macular degeneration (4 arms), sponsored by Allergan. Primary endpoint: Percentage of Patients With Improvement in Best Corrected Visual Acuity (BCVA) of 15 or More Letters at Month 3. Started Jan 2007; status: terminated.
02
Drugs
Sirna-027
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00395057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395057.